Nymox Drug for Benign Prostatic Hyperplasia Holds Promise

Nymox Pharmaceutical's lead drug candidate NX-1207 for the treatment of benign prostatic hyperplasia (BPH) shows good promise as a potential first-line treatment for BPH.

In two completed trials in the U.S. to date, the drug has shown highly significant efficacy without significant side effects. The company's large Phase II trial is expected to be completed later this year.

In the Phase I/II trials to date, after 30 days, the subjects treated with NX-1207 showed a statistically significant overall mean symptom improvement of 6.87 points (compared to 0.5 for controls) and a statistically significant shrinkage in prostate size. There were no significant adverse side effects from the drug in these trials. Subjects followed up after one year also showed a statistically significant symptom improvement of 8.8 points compared to controls.